A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29 Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Laurie, Scott Andrew
  • Solomon, Benjamin J
  • Seymour, Lesley
  • Ellis, Peter
  • Goss, Glenwood D
  • Shepherd, Frances A
  • Boyer, Michael J
  • Arnold, Andrew
  • Clingan, Philip
  • Laberge, Francis
  • Fenton, Dave
  • Hirsh, Vera
  • Zukin, Mauro
  • Stockler, Martin R
  • Lee, Christopher W
  • Chen, Eric Xueyu
  • Montenegro, Alexander
  • Ding, Keyue
  • Bradbury, Penelope Ann

publication date

  • May 20, 2012